0.0550CAD+10.00%Mkt Cap: 10.88M CADP/E: —Last update: 2026-05-26
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II cli…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap10.88M CAD
Enterprise Value13.45M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-4.71M CAD
Revenue/Share—
Last Price0.0550 CAD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees—
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.36
PEG—
EV/EBITDA-3.43
EV/Revenue—
P/S—
P/B-2.63
EPS (TTM)-0.03
EPS (Forward)-0.14
52W Range
0.05005% of range0.1600
52W High0.1600 CAD
52W Low0.0500 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE94.80%
ROA-556.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.53M CAD
CapEx (TTM)—
FCF Margin—
FCF Yield-38.33%
Net Debt2.14M CAD
Net Debt/EBITDA-0.55
Balance Sheet
Debt/Equity-0.72
Current Ratio1.54
Quick Ratio1.52
Book Value/Sh-0.0190 CAD
Cash/Share0.0070 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateDec 30, 2020
Splits
Last Split1:20
Split DateDec 30, 2020
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.197.82M
Float149.39M
Insiders17.76%
Institutions0.00%
Short Interest
Short Ratio0.2d
Short % Out.0.00%
Shares Short16.34K
Short (prev mo.)5.16K
Technical
SMA 500.0668 (-17.7%)
SMA 2000.0856 (-35.7%)
Beta0.58
S&P 52W Chg28.31%
Avg Vol (30d)37.96K
Avg Vol (10d)51.58K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—